Loading
companiesCompany
SecuraBio
SecuraBio is a US company that owns the PI3K inhibitor duvelisib (Copiktra), acquired from Verastem in 2020, for relapsed chronic lymphocytic leukaemia and follicular lymphoma.
Also called: Secura BioSecura Bio, Inc.
Overview
SecuraBio, a privately held company based in Las Vegas, acquired worldwide rights to duvelisib (Copiktra) from Verastem Oncology in 2020. Duvelisib, an oral inhibitor of PI3K-delta and PI3K-gamma, is approved in the United States for relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma after two prior therapies; its follicular lymphoma indication was withdrawn in 2021, and the FDA added a boxed warning in 2022 after a survival analysis of the DUO trial. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Las Vegas, NV, US
Scorecard
All companies#190of 1244 companies, score 31
- approved products +6
- targets +2
- modalities +2
- regions +2
- registry trials +22
- failures -3
1 approved, 0 in phase 3, 0 earlier, 1 targets, 117 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
ApprovedSmall-molecule PI3Kδ/γ inhibitor
Duvelisib · Copiktra
A dual PI3K inhibitor for relapsed CLL whose survival data raised FDA concern; use is now limited to late lines.
ApprovedPan-HDAC inhibitor
Panobinostat · Farydak
An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed.
Similar pages
- CompanyTG Therapeutics
Shares PI3K delta (PIK3CD), Follicular lymphoma, Chronic lymphocytic leukaemia.
- CompanyInfinity Pharmaceuticals
Shares Duvelisib, Chronic lymphocytic leukaemia.
- CompanyMEI Pharma
Shares PI3K delta (PIK3CD), Follicular lymphoma.
- TreatmentCopanlisib
Shares PI3K delta (PIK3CD), Follicular lymphoma.
- TreatmentIdelalisib
Shares PI3K delta (PIK3CD), Follicular lymphoma, Chronic lymphocytic leukaemia.
- TermInfection prophylaxis in lymphoma: PJP, herpes, fungal risk and vaccination
Shares Duvelisib, Follicular lymphoma.
- TreatmentBendamustine
Shares A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype, Follicular lymphoma, Chronic lymphocytic leukaemia.
cancers
fronts
targets
drugs
ApprovedSmall-molecule PI3Kδ/γ inhibitor
Duvelisib · Copiktra
ApprovedPan-HDAC inhibitor
Panobinostat · Farydak